Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study

IF 3.8 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Academic Radiology Pub Date : 2024-12-01 DOI:10.1016/j.acra.2024.05.033

Kun Ji , Yang Shi , Zhiying Liang , Cong Zhang , Li Jing , Tiantian Xu , Shoujin Cao , Guanhui Zhou , Yunbo Cao , Jiahua Niu , Jinghua Zhu , Jing Ai , Zhen Li , Feng Chen

{"title":"Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study","authors":"Kun Ji , Yang Shi , Zhiying Liang , Cong Zhang , Li Jing , Tiantian Xu , Shoujin Cao , Guanhui Zhou , Yunbo Cao , Jiahua Niu , Jinghua Zhu , Jing Ai , Zhen Li , Feng Chen","doi":"10.1016/j.acra.2024.05.033","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale and Objectives</h3><div>This study aimed to propose a novel approach of lipiodol<span><span> combined with drug-eluting beads transarterial chemoembolization (Lipiodol-DEB TACE) and to compare the safety and efficacy with DEB-TACE alone for patients with unresectable </span>hepatocellular carcinoma (HCC).</span></div></div><div><h3>Materials and Methods</h3><div><span>From the database of four centers, the records of patients with HCC who received DEB-TACE or Lipiodol-DEB TACE as initial treatment were retrospectively evaluated. The tumor response was measured based on the Modified Response Evaluation Criteria in Solid Tumors. </span>Overall survival<span> (OS), progression-free survival (PFS) and adverse events (AEs) were compared between two groups.</span></div></div><div><h3>Results</h3><div>A total of 244 patients were included with 160 patients receiving DEB-TACE and 84 patients receiving Lipiodol-DEB TACE. Lipiodol-DEB TACE group had higher objective response rate (86.9 % vs. 76.3 %), higher disease control rate (97.6 % vs. 88.8 %), longer median OS (42.6 vs. 25.8 months) and longer median PFS (34.0 vs. 17.0 months) than DEB-TACE group (<em>P</em><span><span> < 0.05). There was no significant difference observed in the incidence of AEs between two groups. Cox analysis identified total bilirubin level, maximum tumor diameter, TACE method and </span>portal vein<span> invasion as independent prognostic factors.</span></span></div></div><div><h3>Conclusion</h3><div>Lipiodol-DEB TACE was a safe option and associated with improved tumor response and survival outcome compared to DEB-TACE alone for selected patients with HCC.</div></div>","PeriodicalId":50928,"journal":{"name":"Academic Radiology","volume":"31 12","pages":"Pages 4912-4922"},"PeriodicalIF":3.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Academic Radiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1076633224003404","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Rationale and Objectives

This study aimed to propose a novel approach of lipiodol combined with drug-eluting beads transarterial chemoembolization (Lipiodol-DEB TACE) and to compare the safety and efficacy with DEB-TACE alone for patients with unresectable hepatocellular carcinoma (HCC).

Materials and Methods

From the database of four centers, the records of patients with HCC who received DEB-TACE or Lipiodol-DEB TACE as initial treatment were retrospectively evaluated. The tumor response was measured based on the Modified Response Evaluation Criteria in Solid Tumors. Overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were compared between two groups.

Results

A total of 244 patients were included with 160 patients receiving DEB-TACE and 84 patients receiving Lipiodol-DEB TACE. Lipiodol-DEB TACE group had higher objective response rate (86.9 % vs. 76.3 %), higher disease control rate (97.6 % vs. 88.8 %), longer median OS (42.6 vs. 25.8 months) and longer median PFS (34.0 vs. 17.0 months) than DEB-TACE group (P < 0.05). There was no significant difference observed in the incidence of AEs between two groups. Cox analysis identified total bilirubin level, maximum tumor diameter, TACE method and portal vein invasion as independent prognostic factors.

Conclusion

Lipiodol-DEB TACE was a safe option and associated with improved tumor response and survival outcome compared to DEB-TACE alone for selected patients with HCC.

查看原文本刊更多论文

经动脉化疗栓塞治疗肝细胞癌的脂肪碘联合药物洗脱珠与单独药物洗脱珠：一项多中心研究。

依据和目的：本研究旨在提出一种新方法，即脂肪碘联合药物洗脱珠经动脉化疗栓塞术（Lipiodol-DEB TACE），并比较其与单纯DEB-TACE治疗不可切除肝细胞癌（HCC）患者的安全性和有效性：从四个中心的数据库中，对接受 DEB-TACE 或 Lipiodol-DEB TACE 作为初始治疗的 HCC 患者的记录进行回顾性评估。肿瘤反应根据实体瘤改良反应评估标准进行测量。比较了两组患者的总生存期（OS）、无进展生存期（PFS）和不良反应（AEs）：结果：共纳入244例患者，其中160例接受DEB-TACE，84例接受Lipiodol-DEB TACE。与 DEB-TACE 组相比，Lipiodol-DEB TACE 组的客观反应率更高（86.9% 对 76.3%），疾病控制率更高（97.6% 对 88.8%），中位 OS 更长（42.6 个月对 25.8 个月），中位 PFS 更长（34.0 个月对 17.0 个月）（P 结论：Lipiodol-DEB TACE 组的客观反应率和疾病控制率均高于 DEB-TACE 组：与单独使用 DEB-TACE 相比，对选定的 HCC 患者而言，脂肪碘-DEB TACE 是一种安全的选择，并能改善肿瘤反应和生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Academic Radiology 医学-核医学

CiteScore

7.60

自引率

10.40%

发文量

432

审稿时长

18 days

期刊介绍： Academic Radiology publishes original reports of clinical and laboratory investigations in diagnostic imaging, the diagnostic use of radioactive isotopes, computed tomography, positron emission tomography, magnetic resonance imaging, ultrasound, digital subtraction angiography, image-guided interventions and related techniques. It also includes brief technical reports describing original observations, techniques, and instrumental developments; state-of-the-art reports on clinical issues, new technology and other topics of current medical importance; meta-analyses; scientific studies and opinions on radiologic education; and letters to the Editor.